In drug discovery, companies face a long timeline and steep costs to receive drug approvals. The likelihood of getting to market successfully is less than 10%, according to a 2022 study.
“Even small advancements in time-to-lead optimization and improvements in the likelihood of clinical success are important to addressing the thousands of diseases that today have no known treatment or cure,” writes Anthony Costa, NVIDIA director of digital biology, in a HealthTech article.
Artificial intelligence helps with process control during drug production and can speed up time to market. Drug discovery…
